Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs

The purpose of this paper was to establish proof of concept for administration of human recombinant F.IX (rF.IX) by inhalation for therapy of hemophilia B. The pharmacokinetics of intratracheal (IT) administration of rF.IX was studied in nine hemophilia B dogs randomized into 3 groups that received...

Full description

Saved in:
Bibliographic Details
Published inThrombosis and haemostasis Vol. 85; no. 3; p. 445
Main Authors Russell, K E, Read, M S, Bellinger, D A, Leitermann, K, Rup, B J, McCarthy, K P, Keith, Jr, J C, Khor, S P, Schaub, R G, Nichols, T C
Format Journal Article
LanguageEnglish
Published Germany 01.03.2001
Subjects
Administration, Inhalation
Animals
Antibodies, Heterophile - blood
Biological Availability
Disease Models, Animal
Dog Diseases - drug therapy
Dogs
Dose-Response Relationship, Drug
Factor IX - administration & dosage
Factor IX - immunology
Factor IX - pharmacokinetics
Hemophilia B - drug therapy
Hemophilia B - veterinary
Humans
Injections, Intravenous
Recombinant Proteins - administration & dosage
Recombinant Proteins - immunology
Recombinant Proteins - pharmacokinetics
Therapeutic Equivalency
Online AccessGet more information

Cover

More Information
Summary:The purpose of this paper was to establish proof of concept for administration of human recombinant F.IX (rF.IX) by inhalation for therapy of hemophilia B. The pharmacokinetics of intratracheal (IT) administration of rF.IX was studied in nine hemophilia B dogs randomized into 3 groups that received 200 IU/kg IT, 1,000 IU/kg IT, or 200 IU/kg intravenously (IV). IT rF.IX produced therapeutic levels of F.IX antigen and activity and the pharmacokinetic parameters were consistent with a slow release from a depot site within the lungs. Bioavailability compared to IV administration was 11% for 200 IU/kg IT and 4.9% for 1,000 IU/kg. The whole blood clotting time began to shorten at 2 h but F.IX bioactivity was not detected until 8 h post infusion in both IT groups. In all groups, F.IX activity was detected through 72 h post administration. These data demonstrate that biologically active rF.IX can reach the systemic circulation when given IT. Aerosolization of rF.IX may provide a needle-free therapeutic option for delivery of rF.IX to hemophilia B patients.
ISSN:0340-6245
DOI:10.1055/s-0037-1615602